US4444784A
(en)
*
|
1980-08-05 |
1984-04-24 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US4432996A
(en)
*
|
1980-11-17 |
1984-02-21 |
Merck & Co., Inc. |
Hypocholesterolemic fermentation products and process of preparation
|
JPS57185275A
(en)
*
|
1981-05-07 |
1982-11-15 |
Sankyo Co Ltd |
Tetrahydro-dum-4 and tetrahydro-isodum-4 and their derivatives
|
JPS57185276A
(en)
*
|
1981-05-11 |
1982-11-15 |
Sankyo Co Ltd |
Dihydro-dum-4 and dihydro-isodum-4 and their derivative
|
JPS5815968A
(ja)
*
|
1981-07-21 |
1983-01-29 |
Sankyo Co Ltd |
Ml−236b誘導体およびその製法
|
JPS5835144A
(ja)
*
|
1981-08-27 |
1983-03-01 |
Sankyo Co Ltd |
Mb−530b誘導体およびその製造法
|
JPS5889191A
(ja)
*
|
1981-11-20 |
1983-05-27 |
Sankyo Co Ltd |
3−ヒドロキシ−ml−236b誘導体の製造法
|
PH20405A
(en)
*
|
1983-07-21 |
1987-01-05 |
Fujisawa Pharmaceutical Co |
Anti-tumor agent container fr.900216 substance or its pharmaceutically acceptable salts thereof
|
CA1282425C
(en)
*
|
1984-06-04 |
1991-04-02 |
Meyer Sletzinger |
Process for preparing hmg-coa reductase inhibitors with a 3,5-dihydroxypentanoate subunit
|
US4611068A
(en)
*
|
1984-11-19 |
1986-09-09 |
Merck Frosst Canada, Inc. |
Process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein
|
EP0204287A3
(en)
*
|
1985-06-04 |
1987-07-01 |
Merck & Co. Inc. |
Process for the preparation of hmg-coa reductase inhibitors with a 3,5-dihydroxypentanoate subunit
|
USRE33033E
(en)
*
|
1985-07-05 |
1989-08-22 |
Merck & Co., Inc. |
Process for the preparation of HMG-CoA reductase inhibitors intermediates
|
US4611081A
(en)
*
|
1985-07-05 |
1986-09-09 |
Merck & Co., Inc. |
Process for the preparation of HMG-CoA reductase inhibitors intermediates
|
US4668699A
(en)
*
|
1985-08-05 |
1987-05-26 |
Merck & Co., Inc. |
Novel HMG-CoA reductase inhibitors
|
US5272174A
(en)
*
|
1985-09-13 |
1993-12-21 |
Sankyo Company, Limited |
Hydroxy-ML-236B derivatives, their preparation and use
|
DE3682557D1
(de)
*
|
1985-09-13 |
1992-01-02 |
Sankyo Co |
Hydroxy-ml-236b-derivate, deren herstellung und anwendung.
|
JPH0633312B2
(ja)
*
|
1986-05-02 |
1994-05-02 |
大正製薬株式会社 |
14−ハイドロキシエリスロマイシン誘導体およびその製造方法
|
US4864038A
(en)
*
|
1986-05-05 |
1989-09-05 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US4937264A
(en)
*
|
1986-05-05 |
1990-06-26 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
EP0245004A3
(en)
*
|
1986-05-05 |
1989-07-26 |
Merck & Co. Inc. |
Antihypercholesterolemic compounds
|
EP0245990A3
(en)
*
|
1986-05-05 |
1989-07-19 |
Merck & Co. Inc. |
Antihypercholesterolemic compounds
|
US4771071A
(en)
*
|
1986-05-05 |
1988-09-13 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US4766145A
(en)
*
|
1986-05-05 |
1988-08-23 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
EP0245003A3
(en)
*
|
1986-05-05 |
1989-07-19 |
Merck & Co. Inc. |
Antihypercholesterolemic compounds
|
US4847306A
(en)
*
|
1986-05-05 |
1989-07-11 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US4661483A
(en)
*
|
1986-05-05 |
1987-04-28 |
Merck & Co., Inc. |
Antihypercholesterolemic lactone compounds, compositions and use
|
US4940727A
(en)
*
|
1986-06-23 |
1990-07-10 |
Merck & Co., Inc. |
Novel HMG-CoA reductase inhibitors
|
USRE36481E
(en)
*
|
1986-06-23 |
2000-01-04 |
Merck & Co., Inc. |
HMG-CoA reductase inhibitors
|
US5116870A
(en)
*
|
1986-06-23 |
1992-05-26 |
Merck & Co., Inc. |
HMG-CoA reductase inhibitors
|
EP0276807A3
(en)
*
|
1987-01-27 |
1988-10-12 |
Warner-Lambert Company |
Lipid regulating compositions
|
US4833258A
(en)
*
|
1987-02-17 |
1989-05-23 |
Merck & Co., Inc. |
Intermediates useful in the preparation of HMG-COA reductase inhibitors
|
EP0306263B1
(en)
*
|
1987-09-02 |
1992-03-18 |
Merck & Co. Inc. |
Novel hmg-coa reductase inhibitors
|
US4997848A
(en)
|
1987-10-27 |
1991-03-05 |
Sankyo Company, Limited |
Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition
|
US4857547A
(en)
*
|
1988-01-07 |
1989-08-15 |
Merck & Co., Inc. |
Novel HMG-CoA reductase inhibitors
|
US5021453A
(en)
*
|
1988-03-02 |
1991-06-04 |
Merck & Co., Inc. |
3-keto HMG-CoA reductase inhibitors
|
US5047549A
(en)
*
|
1988-03-21 |
1991-09-10 |
E. R. Squibb & Sons, Inc. |
Derivatives of pravastatin for inhibiting cholesterol biosynthesis
|
US4857522A
(en)
*
|
1988-03-21 |
1989-08-15 |
E. R. Squibb & Sons, Inc. |
Derivatives of pravastatin for inhibiting cholesterol biosynthesis
|
US5155229A
(en)
*
|
1988-03-21 |
1992-10-13 |
E. R. Squibb & Sons, Inc. |
Derivatives of pravastatin and method of making the same
|
US5180589A
(en)
*
|
1988-03-31 |
1993-01-19 |
E. R. Squibb & Sons, Inc. |
Pravastatin pharmaceuatical compositions having good stability
|
US5030447A
(en)
*
|
1988-03-31 |
1991-07-09 |
E. R. Squibb & Sons, Inc. |
Pharmaceutical compositions having good stability
|
US4997755A
(en)
*
|
1988-04-15 |
1991-03-05 |
Merck & Co., Inc. |
HMG-CoA reductase inhibitors produced by Nocardia sp. (MA 6455)
|
US4963538A
(en)
*
|
1988-06-29 |
1990-10-16 |
Merck & Co., Inc. |
5-oxygenated HMG-CoA reductase inhibitors
|
US5075327A
(en)
*
|
1988-08-10 |
1991-12-24 |
Hoffmann-La Roche Inc. |
Antipsoriatic agents
|
US5021451A
(en)
*
|
1988-11-14 |
1991-06-04 |
Hoffman-La Roche Inc. |
Method for inhibiting hyperproliferative diseases
|
US5200549A
(en)
*
|
1988-11-14 |
1993-04-06 |
Hoffman-La Roche Inc. |
Antipsoriatic agents
|
US5073568A
(en)
*
|
1988-11-14 |
1991-12-17 |
Hoffmann-La Roche Inc. |
Antipsoriatic agents
|
US5376383A
(en)
*
|
1988-11-21 |
1994-12-27 |
Merck & Co., Inc. |
Method for enhancing the lowering of plasma-cholesterol levels
|
US5260305A
(en)
*
|
1988-12-12 |
1993-11-09 |
E. R. Squibb & Sons, Inc. |
Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
|
JP2763782B2
(ja)
*
|
1989-02-14 |
1998-06-11 |
旭電化工業株式会社 |
メバロン酸の製造方法
|
US5166364A
(en)
*
|
1989-02-27 |
1992-11-24 |
E. R. Squibb & Sons, Inc. |
Mevinic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
|
CA2016467A1
(en)
|
1989-06-05 |
1990-12-05 |
Martin Eisman |
Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
|
US5001148A
(en)
*
|
1989-06-07 |
1991-03-19 |
E. R. Squibb & Sons, Inc. |
Mevinic acid derivatives
|
US5001241A
(en)
*
|
1989-06-09 |
1991-03-19 |
Merck & Co., Inc. |
3-KETO HMG-CoA reductase inhibitors
|
US5041562A
(en)
*
|
1989-06-09 |
1991-08-20 |
Merck & Co., Inc. |
3-keto HMG-CoA reductase inhibitors
|
US4937259A
(en)
*
|
1989-06-09 |
1990-06-26 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US5102911A
(en)
*
|
1989-06-09 |
1992-04-07 |
Merck & Co, Inc. |
4-Substituted HMG-CoA reductase inhibitors
|
US5010105A
(en)
*
|
1989-06-09 |
1991-04-23 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US4970231A
(en)
*
|
1989-06-09 |
1990-11-13 |
Merck & Co., Inc. |
4-substituted HMG-CoA reductase inhibitors
|
US4997849A
(en)
*
|
1989-06-23 |
1991-03-05 |
Merck & Co., Inc. |
Microbial transformation of simvastatin
|
US4965200A
(en)
*
|
1989-06-23 |
1990-10-23 |
Merck & Co., Inc. |
Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs
|
FI94339C
(fi)
|
1989-07-21 |
1995-08-25 |
Warner Lambert Co |
Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
|
US5316765A
(en)
*
|
1989-09-07 |
1994-05-31 |
Karl Folkers Foundation For Biomedical And Clinical Research |
Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
|
US5212296A
(en)
*
|
1989-09-11 |
1993-05-18 |
E. I. Du Pont De Nemours And Company |
Expression of herbicide metabolizing cytochromes
|
US5173487A
(en)
*
|
1989-11-13 |
1992-12-22 |
E. R. Squibb & Sons, Inc. |
Mevinic acid derivatives
|
US5177104A
(en)
*
|
1990-04-03 |
1993-01-05 |
E. R. Squibb & Sons, Inc. |
6-α-hydroxy derivatives of mevinic acids
|
GB9007738D0
(en)
*
|
1990-04-05 |
1990-06-06 |
British Bio Technology |
Compounds
|
US5089523A
(en)
*
|
1990-05-11 |
1992-02-18 |
E. R. Squibb & Sons, Inc. |
Fluorinated derivatives of mevinic acids
|
US6630502B2
(en)
|
1990-05-15 |
2003-10-07 |
E.R. Squibb & Sons, Inc. |
Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
|
US5140012A
(en)
*
|
1990-05-31 |
1992-08-18 |
E. R. Squibb & Sons, Inc. |
Method for preventing onset of restenosis after angioplasty employing pravastatin
|
US5622985A
(en)
*
|
1990-06-11 |
1997-04-22 |
Bristol-Myers Squibb Company |
Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
|
US5264455A
(en)
*
|
1990-07-06 |
1993-11-23 |
E. R. Squibb & Sons, Inc. |
Sulfur-substituted mevinic acid derivatives
|
US5223415A
(en)
*
|
1990-10-15 |
1993-06-29 |
Merck & Co., Inc. |
Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)
|
IE75349B1
(en)
*
|
1991-03-07 |
1997-08-27 |
Lonza Ag |
A process for the terminal hydroxylation of ethyl groups on aromatic 5- or 6-membered heterocyclic compounds
|
US5225202A
(en)
*
|
1991-09-30 |
1993-07-06 |
E. R. Squibb & Sons, Inc. |
Enteric coated pharmaceutical compositions
|
US5286746A
(en)
*
|
1991-12-20 |
1994-02-15 |
E. R. Squibb & Sons, Inc. |
Sulfur-substituted mevinic acid derivatives
|
US5620876A
(en)
*
|
1992-04-29 |
1997-04-15 |
E. R. Squibb & Sons, Inc. |
Enzymatic hydrolysis and esterification processes for the preparation of HMG-CoA reductase inhibitors and intermediates thereof
|
FI932188A
(fi)
|
1992-05-15 |
1993-11-16 |
Sankyo Co |
Oktahydronaftalenoximderivat foer inhibering av kolesterolbiosyntesen, deras framstaellning och anvaendning
|
US5369123A
(en)
*
|
1992-10-09 |
1994-11-29 |
E. R. Squibb & Sons, Inc. |
Nitrogen-substituted mevinic acid derivatives useful as HMG-CoA reductase inhibitors
|
NZ250609A
(en)
*
|
1992-12-28 |
1995-07-26 |
Sankyo Co |
Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
|
IL108432A
(en)
*
|
1993-01-29 |
1997-09-30 |
Sankyo Co |
DERIVATIVES OF 3, 5-DIHYDROXY-7- £1, 2, 6, 7, 8, 8a-HEXAHYDRO-2- METHYL-8- (SUBSTITUTED ALKANOYLOXY)-1-NAPHTHYL| HEPTANOIC ACID AND THEIR LACTONES, THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
|
FR2709126B1
(fr)
*
|
1993-08-18 |
1995-09-29 |
Adir |
Nouveaux dérivés de naphtalène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
|
US6043064A
(en)
*
|
1993-10-22 |
2000-03-28 |
Bristol-Myers Squibb Company |
Enzymatic hydroxylation process for the preparation of HMG-CoA reductase inhibitors and intermediates thereof
|
JPH09504436A
(ja)
*
|
1993-11-02 |
1997-05-06 |
メルク エンド カンパニー インコーポレーテッド |
トリオールポリケチドシンターゼをコードするdna
|
WO1995013063A1
(en)
*
|
1993-11-09 |
1995-05-18 |
Merck & Co., Inc. |
HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
|
US6369103B1
(en)
|
1994-01-18 |
2002-04-09 |
Bristol-Myers Squibb Company |
Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
|
US5681278A
(en)
*
|
1994-06-23 |
1997-10-28 |
Cormedics Corp. |
Coronary vasculature treatment method
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
US6262277B1
(en)
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
US6268392B1
(en)
|
1994-09-13 |
2001-07-31 |
G. D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
|
US5942423A
(en)
|
1995-06-07 |
1999-08-24 |
Massachusetts Institute Of Technology |
Conversion of compactin to pravastatin by actinomadura
|
US5616595A
(en)
*
|
1995-06-07 |
1997-04-01 |
Abbott Laboratories |
Process for recovering water insoluble compounds from a fermentation broth
|
US5900433A
(en)
*
|
1995-06-23 |
1999-05-04 |
Cormedics Corp. |
Vascular treatment method and apparatus
|
TW474809B
(en)
*
|
1995-07-03 |
2002-02-01 |
Sankyo Co |
A pharmaceutical composition for arteriosclerosis or xanthoma consisting of HMG-CoA reductase inhibitors and insulin sensitizers
|
KR100186758B1
(ko)
*
|
1996-08-09 |
1999-04-01 |
영진약품공업 주식회사 |
프라바스타틴(pravastatin)전구체의제조방법
|
US6066653A
(en)
*
|
1997-01-17 |
2000-05-23 |
Bristol-Myers Squibb Co. |
Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
|
CA2276467A1
(en)
*
|
1997-01-17 |
1998-07-23 |
Bristol-Myers Squibb Company |
Method for treating atherosclerosis with an mpt inhibitor and cholesterol lowering drugs
|
KR100210482B1
(ko)
*
|
1997-04-10 |
1999-07-15 |
김종인 |
스트렙토마이세스엑스포리아투스(streptomycesexfoliatus)yj-118과이를이용한프라바스타틴나트륨의제조방법
|
EP0877089A1
(en)
|
1997-05-07 |
1998-11-11 |
Gist-Brocades B.V. |
HMG-CoA reductase inhibitor preparation process
|
US20010006644A1
(en)
|
1997-07-31 |
2001-07-05 |
David J. Bova |
Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
|
JP4162848B2
(ja)
|
1997-08-07 |
2008-10-08 |
協和醗酵工業株式会社 |
HMG−CoAレダクターゼ阻害剤の製造法
|
AU9264598A
(en)
*
|
1997-08-22 |
1999-03-16 |
Gist-Brocades B.V. |
Statin production by fermentation
|
GT199800127A
(es)
*
|
1997-08-29 |
2000-02-01 |
|
Combinaciones terapeuticas.
|
US6177121B1
(en)
|
1997-09-29 |
2001-01-23 |
Purdue Research Foundation |
Composition and method for producing low cholesterol eggs
|
US6147109A
(en)
*
|
1997-10-14 |
2000-11-14 |
The General Hospital Corporation |
Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
|
US6083497A
(en)
|
1997-11-05 |
2000-07-04 |
Geltex Pharmaceuticals, Inc. |
Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
|
US20080275104A1
(en)
*
|
1997-11-25 |
2008-11-06 |
Musc Foundation For Research Development |
Methods of treating juvenile type 1 diabetes mellitus
|
US20040029962A1
(en)
*
|
1997-12-12 |
2004-02-12 |
Chih-Ming Chen |
HMG-COA reductase inhibitor extended release formulation
|
US8679534B2
(en)
*
|
1997-12-12 |
2014-03-25 |
Andrx Labs, Llc |
HMG-CoA reductase inhibitor extended release formulation
|
US6180597B1
(en)
|
1998-03-19 |
2001-01-30 |
Brigham And Women's Hospital, Inc. |
Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
|
SI9800144A
(sl)
*
|
1998-05-21 |
1999-12-31 |
LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. |
Nov biotehnološki postopek pridobivanja 3-hidroksi-ML-236B derivatov poznanih kot M-4 in M-4'
|
US20030078211A1
(en)
*
|
1998-06-24 |
2003-04-24 |
Merck & Co., Inc. |
Compositions and methods for inhibiting bone resorption
|
AU757104B2
(en)
|
1998-06-24 |
2003-01-30 |
Merck & Co., Inc. |
Compositions and methods for inhibiting bone resorption
|
US6423751B1
(en)
|
1998-07-14 |
2002-07-23 |
The Brigham And Women's Hospital, Inc. |
Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
|
US5985907A
(en)
*
|
1998-08-12 |
1999-11-16 |
Health Research, Inc. |
Method for inhibiting growth of methanogens
|
SI20070A
(sl)
*
|
1998-09-18 |
2000-04-30 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Nove soli inhibitorjev HMG-CoA reduktaze
|
SI20305A
(sl)
*
|
1999-08-06 |
2001-02-28 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Kristali natrijeve soli pravastatina
|
US20080213378A1
(en)
*
|
1998-10-01 |
2008-09-04 |
Elan Pharma International, Ltd. |
Nanoparticulate statin formulations and novel statin combinations
|
US8293277B2
(en)
*
|
1998-10-01 |
2012-10-23 |
Alkermes Pharma Ireland Limited |
Controlled-release nanoparticulate compositions
|
EP1133281A1
(en)
|
1998-11-20 |
2001-09-19 |
RTP Pharma Inc. |
Dispersible phospholipid stabilized microparticles
|
SI20109A
(sl)
*
|
1998-12-16 |
2000-06-30 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Stabilna farmacevtska formulacija
|
US6391583B1
(en)
|
1998-12-18 |
2002-05-21 |
Wisconsin Alumni Research Foundation |
Method of producing antihypercholesterolemic agents
|
KR20010099937A
(ko)
|
1998-12-23 |
2001-11-09 |
윌리암스 로저 에이 |
심혈관 징후용 콜레스테릴 에스테르 전달 단백질 억제제및 피브르산 유도체의 조합물
|
PL348508A1
(en)
*
|
1998-12-23 |
2002-05-20 |
Searle Llc |
Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
|
JP2002533414A
(ja)
|
1998-12-23 |
2002-10-08 |
ジー.ディー.サール エルエルシー |
心臓血管に適用するための回腸胆汁酸輸送阻害剤および胆汁酸隔離剤の組み合わせ
|
DE69911058T2
(de)
*
|
1998-12-23 |
2004-06-03 |
G.D. Searle Llc, Chicago |
Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen
|
CN1342090A
(zh)
|
1998-12-23 |
2002-03-27 |
G·D·瑟尔有限公司 |
适用于心血管疾病的回肠胆汁酸转运抑制剂和贝酸衍生物的组合
|
JP2002533408A
(ja)
|
1998-12-23 |
2002-10-08 |
ジー.ディー.サール エルエルシー |
心臓血管に適用するためのコレステリルエステル転送タンパク質阻害剤およびニコチン酸誘導体の組み合わせ
|
US6462091B1
(en)
|
1998-12-23 |
2002-10-08 |
G.D. Searle & Co. |
Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
|
EP1340510A1
(en)
|
1998-12-23 |
2003-09-03 |
G.D. Searle LLC. |
Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
|
AU3074300A
(en)
|
1999-01-20 |
2000-08-07 |
Kyowa Hakko Kogyo Co. Ltd. |
Process for producing hmg-coa reductase inhibitors
|
CZ20012728A3
(cs)
*
|
1999-01-29 |
2002-02-13 |
Kyowa Hakko Kogyo Co., Ltd. |
Způsob výroby inhibitorů HMG-CoA reduktasy
|
US6682913B1
(en)
|
1999-02-03 |
2004-01-27 |
Institute For Drug Research Ltd. |
Microbial process for preparing pravastatin
|
US6569461B1
(en)
|
1999-03-08 |
2003-05-27 |
Merck & Co., Inc. |
Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
|
HUP9902352A1
(hu)
*
|
1999-07-12 |
2000-09-28 |
Gyógyszerkutató Intézet Kft. |
Eljárás pravasztatin mikrobiológiai előállítására
|
SE9903028D0
(sv)
*
|
1999-08-27 |
1999-08-27 |
Astra Ab |
New use
|
UA77151C2
(en)
*
|
1999-08-30 |
2006-11-15 |
Sanofi Aventis Deutschland |
Use of ramipril for prevention of cardiovascular events
|
CN1754872A
(zh)
|
1999-11-30 |
2006-04-05 |
特瓦药厂有限公司 |
从发酵肉汤中回收抑素化合物的方法
|
CZ20021998A3
(cs)
*
|
1999-12-14 |
2003-02-12 |
Biogal Gyogyszergyar Rt. |
Nové formy sodné soli pravastatinu
|
IN191580B
(da)
*
|
1999-12-17 |
2003-12-06 |
Ranbaxy Lab Ltd |
|
CA2398199A1
(en)
*
|
2000-01-28 |
2001-08-02 |
Asahi Kasei Kabushiki Kaisha |
Novel therapeutic agents that use a .beta.3 agonist
|
ES2328446T5
(es)
*
|
2000-02-04 |
2014-02-27 |
Children's Hospital Research Foundation |
Uso de lipasa ácida lisosomal para tratar la aterosclerosis y enfermedades asociadas
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
WO2001068096A2
(en)
*
|
2000-03-10 |
2001-09-20 |
Pharmacia Corporation |
Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
|
EP1286984A2
(en)
|
2000-03-10 |
2003-03-05 |
Pharmacia Corporation |
Method for the preparation of tetrahydrobenzothiepines
|
ES2401598T3
(es)
|
2000-04-10 |
2013-04-22 |
Teva Pharmaceutical Industries, Ltd. |
Composiciones farmacéuticas estables que contienen ácidos 7-sustituido-3,5-dihidroxiheptanoicos o ácidos 7-sustituido-3,5-dihidroxiheptenoicos
|
JP2003530437A
(ja)
*
|
2000-04-13 |
2003-10-14 |
マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ |
Aβ42低下物質
|
DE10030375A1
(de)
*
|
2000-06-21 |
2002-01-03 |
Bayer Ag |
Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
|
WO2002017913A1
(fr)
*
|
2000-08-30 |
2002-03-07 |
Sankyo Company, Limited |
Compositions medicinales utilisees dans la prevention ou le traitement de l'insuffisance cardiaque
|
JO2654B1
(en)
|
2000-09-04 |
2012-06-17 |
شركة جانسين فارماسوتيكا ان. في |
Multiple aryl caroxa amides are useful as lipid - lowering agents
|
US8586094B2
(en)
|
2000-09-20 |
2013-11-19 |
Jagotec Ag |
Coated tablets
|
US6936731B2
(en)
*
|
2000-10-05 |
2005-08-30 |
TEVA Gyógyszergyár Részvénytársaság |
Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
|
US20050215636A1
(en)
*
|
2000-10-05 |
2005-09-29 |
Vilmos Keri |
Pravastatin sodium substantially free of pravastatin lactone and EPI-pravastatin, and compositions containing same
|
NZ525631A
(en)
*
|
2000-10-05 |
2005-05-27 |
Biogal Gyogyszergyar |
Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
|
US6534540B2
(en)
|
2000-10-06 |
2003-03-18 |
George Kindness |
Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor
|
US20030162829A1
(en)
*
|
2000-10-06 |
2003-08-28 |
George Kindness |
Combination of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor
|
JP2002121172A
(ja)
*
|
2000-10-16 |
2002-04-23 |
Sankyo Co Ltd |
プラバスタチン又はその薬理上許容される塩の精製方法
|
JP3236282B1
(ja)
*
|
2000-10-16 |
2001-12-10 |
三共株式会社 |
プラバスタチンを精製する方法
|
US6916849B2
(en)
|
2000-10-23 |
2005-07-12 |
Sankyo Company, Limited |
Compositions for improving lipid content in the blood
|
WO2002038151A1
(fr)
|
2000-11-07 |
2002-05-16 |
Sankyo Company, Limited |
Compositions permettant de reduire la concentration de peroxydes lipidiques
|
US6777552B2
(en)
|
2001-08-16 |
2004-08-17 |
Teva Pharmaceutical Industries, Ltd. |
Processes for preparing calcium salt forms of statins
|
JO2409B1
(en)
*
|
2000-11-21 |
2007-06-17 |
شركة جانسين فارماسوتيكا ان. في |
Second-phenyl carboxy amides are useful as lipid-lowering agents
|
US20030232834A1
(en)
*
|
2001-03-08 |
2003-12-18 |
Keller Bradley T |
Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
|
EP1372616A4
(en)
*
|
2001-03-27 |
2004-06-23 |
Ranbaxy Lab Ltd |
STABLE PHARMACEUTICAL COMPOSITION BASED ON PRAVASTATIN
|
JO2390B1
(en)
*
|
2001-04-06 |
2007-06-17 |
شركة جانسين فارماسوتيكا ان. في |
Diphenylcarboxamides act as lipid-lowering agents
|
AU2002254567B2
(en)
|
2001-04-11 |
2007-10-11 |
Bristol-Myers Squibb Company |
Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
|
JP2004526778A
(ja)
*
|
2001-04-18 |
2004-09-02 |
ジェンザイム コーポレーション |
脂肪族ポリアミンを用いるx症候群の処置方法
|
US6699886B2
(en)
*
|
2001-05-31 |
2004-03-02 |
Cellegy Pharmaceuticals, Inc. |
Store operated calcium influx inhibitors and methods of use
|
WO2003000239A1
(en)
*
|
2001-06-21 |
2003-01-03 |
Andrx Pharmaceuticals, Inc. |
Stable pharmaceutical compositions containing pravastatin
|
US20040180087A1
(en)
*
|
2001-06-21 |
2004-09-16 |
Boyong Li |
Stable controlled release pharmaceutical compositions containing pravastatin
|
US20040077625A1
(en)
*
|
2001-07-25 |
2004-04-22 |
Tremont Samuel J. |
Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
|
US20040092565A1
(en)
*
|
2001-07-25 |
2004-05-13 |
George Kindness |
Composition and method of sustaining chemotherapeutic effect while reducing dose of chemotherapeutic agent using cox-2 inhibitor and statin
|
EP1430138B1
(en)
*
|
2001-09-27 |
2006-01-18 |
Biocon Limited |
Process for producing pravastatin sodium salt using streptomyces flavidovirens dsm 14455
|
KR100414334B1
(ko)
*
|
2001-09-29 |
2004-01-07 |
코바이오텍 (주) |
프라바스타틴 나트륨의 생산 방법
|
JP2005514337A
(ja)
*
|
2001-10-18 |
2005-05-19 |
ブリストル−マイヤーズ スクイブ カンパニー |
ヒトグルカゴン様ペプチド−1模倣体、並びに糖尿病および関連疾患の処置におけるその使用
|
US7238671B2
(en)
*
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
EP1448546A4
(en)
*
|
2001-11-02 |
2005-02-02 |
Searle Llc |
MONO- AND DI-FLUORINATED BENZOTHIEPINE COMPOUNDS AS INHIBITORS OF TRANSPORT OF ACIDICALLY DEPENDENT SODIUM ACILIC (ASBT) BILIARY ACIDS AND TAUROCHOLATE RECOVERY
|
US6806381B2
(en)
*
|
2001-11-02 |
2004-10-19 |
Bristol-Myers Squibb Company |
Process for the preparation of aniline-derived thyroid receptor ligands
|
WO2003043624A1
(en)
*
|
2001-11-16 |
2003-05-30 |
Bristol-Myers Squibb Company |
Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
|
US6831102B2
(en)
*
|
2001-12-07 |
2004-12-14 |
Bristol-Myers Squibb Company |
Phenyl naphthol ligands for thyroid hormone receptor
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
EP1465869B1
(en)
|
2001-12-21 |
2013-05-15 |
Exelixis Patent Company LLC |
Modulators of lxr
|
EP1465882B1
(en)
*
|
2001-12-21 |
2011-08-24 |
X-Ceptor Therapeutics, Inc. |
Hetrocyclic modulators of nuclear receptors
|
JP2005521653A
(ja)
|
2002-01-17 |
2005-07-21 |
ファルマシア コーポレイション |
先端ナトリウム同時依存性胆汁酸輸送(asbt)およびタウロコール酸塩取込みの阻害剤としての新規アルキル/アリールヒドロキシまたはケトチエピン化合物
|
KR100379075B1
(en)
*
|
2002-03-07 |
2003-04-08 |
Jinis Biopharmaceuticals Co |
Method for producing low cholesterol animal food product and food product therefrom
|
WO2003078379A1
(en)
*
|
2002-03-18 |
2003-09-25 |
Biocon Limited |
AMORPHOUS Hmg-CoA REDUCTASE INHIBITORS OF DESIRED PARTICLE SIZE
|
US20050089572A1
(en)
*
|
2002-03-22 |
2005-04-28 |
Manoj Kumar |
Controlled release drug delivery system of pravastatin
|
US20050113577A1
(en)
*
|
2002-04-16 |
2005-05-26 |
Karki Shyam B. |
Solid forms of slats with tyrosine kinase activity
|
US6747048B2
(en)
|
2002-05-08 |
2004-06-08 |
Bristol-Myers Squibb Company |
Pyridine-based thyroid receptor ligands
|
ES2685697T3
(es)
|
2002-05-09 |
2018-10-10 |
The Brigham And Women's Hospital, Inc. |
1L1RL-1 como un marcador de enfermedades cardiovasculares
|
WO2003096548A2
(de)
*
|
2002-05-14 |
2003-11-20 |
Siemens Aktiengesellschaft |
Verfahren zum erzeugen eines sendesignals
|
US7057046B2
(en)
*
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
JP4533134B2
(ja)
*
|
2002-06-10 |
2010-09-01 |
エラン ファーマ インターナショナル,リミティド |
ナノ粒子ポリコサノール製剤および新規なポリコサノールの組合せ
|
US20050182106A1
(en)
*
|
2002-07-11 |
2005-08-18 |
Sankyo Company, Limited |
Medicinal composition for mitigating blood lipid or lowering blood homocysteine
|
CA2493645A1
(en)
*
|
2002-07-23 |
2004-01-29 |
Nutrinova Nutrition Specialties & Food Ingredients Gmbh |
Cholesterol-reducing agent made of dietary fibre and cholesterol-reducing substances
|
US20050182036A1
(en)
*
|
2002-08-02 |
2005-08-18 |
Sankyo Company, Limited |
Medicinal composition containing an HMG-CoA reductase inhibitor
|
US20050187204A1
(en)
*
|
2002-08-08 |
2005-08-25 |
Sankyo Company, Limited |
Medicinal composition for lowering blood lipid level
|
UA79300C2
(en)
*
|
2002-08-12 |
2007-06-11 |
Janssen Pharmaceutica Nv |
N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
|
EP2298315A1
(en)
|
2002-08-28 |
2011-03-23 |
Harbor BioSciences, Inc. |
Therapeutic treatment methods
|
US20080293750A1
(en)
*
|
2002-10-17 |
2008-11-27 |
Anna Helgadottir |
Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
|
US20060019269A1
(en)
*
|
2002-10-17 |
2006-01-26 |
Decode Genetics, Inc. |
Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
|
DE60332856D1
(de)
*
|
2002-10-23 |
2010-07-15 |
Bristol Myers Squibb Co |
Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
|
KR20050083827A
(ko)
*
|
2002-10-24 |
2005-08-26 |
이노스 파마슈티칼스, 인코포레이티드 |
서방성 l-아르기닌 포뮬레이션 및 이의 제조방법 및 용도
|
US20080145424A1
(en)
*
|
2002-10-24 |
2008-06-19 |
Enos Phramaceuticals, Inc. |
Sustained release L-arginine formulations and methods of manufacture and use
|
US7098235B2
(en)
*
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
US20040110241A1
(en)
*
|
2002-12-06 |
2004-06-10 |
Segal Mark S. |
Materials and methods for monitoring vascular endothelial function
|
US20040198800A1
(en)
*
|
2002-12-19 |
2004-10-07 |
Geoffrey Allan |
Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
|
US20040132771A1
(en)
*
|
2002-12-20 |
2004-07-08 |
Pfizer Inc |
Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
|
WO2004056358A1
(en)
|
2002-12-20 |
2004-07-08 |
Pfizer Products Inc. |
Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
|
JP2006523613A
(ja)
|
2002-12-20 |
2006-10-19 |
エスティ.ジェイムス アソシエイト エルエルシー/フェイバー リサーチ シリーズ |
徐放性医薬投与のための被覆粒子
|
DE10261061A1
(de)
*
|
2002-12-24 |
2004-07-15 |
Nutrinova Nutrition Specialties & Food Ingredients Gmbh |
Diätetisches Lebensmittel zur positiven Beeinflussung der kardiovaskulären Gesundheit
|
DE10261067A1
(de)
*
|
2002-12-24 |
2004-08-05 |
Nutrinova Nutrition Specialties & Food Ingredients Gmbh |
Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure
|
US20040176425A1
(en)
*
|
2003-01-24 |
2004-09-09 |
Washburn William N. |
Cycloalkyl containing anilide ligands for the thyroid receptor
|
TW200504021A
(en)
*
|
2003-01-24 |
2005-02-01 |
Bristol Myers Squibb Co |
Substituted anilide ligands for the thyroid receptor
|
WO2004071431A2
(en)
*
|
2003-02-05 |
2004-08-26 |
Myriad Genetics, Inc. |
Method and composition for treating neurodegenerative disorders
|
EP1452602A1
(en)
*
|
2003-02-25 |
2004-09-01 |
Antibiotic Co., |
Method for production of pravastatin by fermentation
|
US7557143B2
(en)
*
|
2003-04-18 |
2009-07-07 |
Bristol-Myers Squibb Company |
Thyroid receptor ligands
|
CA2524175C
(en)
*
|
2003-04-28 |
2016-06-14 |
Sankyo Company Limited |
Sugar intake-ability enhancer
|
EP1621210B1
(en)
|
2003-04-28 |
2013-06-19 |
Daiichi Sankyo Company, Limited |
Adiponectin production enhancer
|
AR041089A1
(es)
|
2003-05-15 |
2005-05-04 |
Merck & Co Inc |
Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
|
US7459474B2
(en)
*
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
KR100470078B1
(ko)
*
|
2003-06-12 |
2005-02-04 |
씨제이 주식회사 |
컴팩틴을 프라바스타틴으로 전환할 수 있는 스트렙토마이세스 종(Streptomyces sp.)CJPV 975652 및 그를 이용한 프라바스타틴의 제조방법
|
EP1790635A3
(en)
*
|
2003-06-18 |
2007-06-13 |
Teva Pharmaceutical Industries, Inc. |
Processes for preparing amorphous fluvastatin sodium
|
US7368468B2
(en)
*
|
2003-06-18 |
2008-05-06 |
Teva Pharmaceutical Industries Ltd. |
Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
|
AU2004311577A1
(en)
*
|
2003-07-11 |
2005-07-21 |
Myriad Genetics, Inc. |
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
|
WO2005007110A2
(en)
*
|
2003-07-11 |
2005-01-27 |
Pro-Pharmaceuticals, Inc. |
Compositions and methods for hydrophobic drug delivery
|
US20050037063A1
(en)
*
|
2003-07-21 |
2005-02-17 |
Bolton Anthony E. |
Combined therapies
|
US6995183B2
(en)
*
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
JP4553899B2
(ja)
|
2003-08-21 |
2010-09-29 |
メルク フロスト カナダ リミテツド |
カテプシンシステインプロテアーゼ阻害剤
|
EP1510208A1
(en)
*
|
2003-08-22 |
2005-03-02 |
Fournier Laboratories Ireland Limited |
Pharmaceutical composition comprising a combination of metformin and statin
|
CA2537271A1
(en)
*
|
2003-08-28 |
2005-03-17 |
Teva Pharmaceutical Industries, Ltd. |
Process for preparation of rosuvastatin calcium
|
RU2358734C2
(ru)
|
2003-08-29 |
2009-06-20 |
Кова Ко., Лтд. |
Способ стабилизации бляшки с высоким содержанием липидов и способ профилактики ее разрушения
|
US20050053664A1
(en)
*
|
2003-09-08 |
2005-03-10 |
Eliezer Zomer |
Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
|
US20050171207A1
(en)
*
|
2003-09-26 |
2005-08-04 |
Myriad Genetics, Incorporated |
Method and composition for combination treatment of neurodegenerative disorders
|
EP1675619A4
(en)
*
|
2003-09-29 |
2010-10-06 |
Palmetto Pharmaceuticals Llc |
EXTENDED RELEASE ARGININE FORMULATIONS, METHODS OF MAKING, AND USES
|
US8227434B1
(en)
|
2003-11-04 |
2012-07-24 |
H. Lee Moffitt Cancer Center & Research Institute, Inc. |
Materials and methods for treating oncological disorders
|
US7390504B2
(en)
*
|
2003-11-07 |
2008-06-24 |
Jj Pharma, Inc. |
HDL-boosting combination therapy complexes
|
US7767828B2
(en)
*
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7576121B2
(en)
*
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7674913B2
(en)
*
|
2003-11-12 |
2010-03-09 |
Phenomix Corporation |
Heterocyclic boronic acid compounds
|
US7317109B2
(en)
*
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
JPWO2005046706A1
(ja)
*
|
2003-11-17 |
2007-05-31 |
株式会社東洋新薬 |
松樹皮抽出物を含む脂質代謝改善剤
|
EP2428516A1
(en)
|
2003-11-19 |
2012-03-14 |
Metabasis Therapeutics, Inc. |
Novel phosphorus-containing thyromimetics
|
EP1601658A1
(en)
*
|
2003-11-24 |
2005-12-07 |
Teva Pharmaceutical Industries Limited |
Crystalline ammonium salts of rosuvastatin
|
JP2007512366A
(ja)
|
2003-11-24 |
2007-05-17 |
テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ |
プラバスタチンの精製方法
|
JP2007512347A
(ja)
*
|
2003-11-26 |
2007-05-17 |
デューク・ユニバーシティー |
緑内障を予防するかまたは治療する方法
|
CN1277826C
(zh)
*
|
2003-12-01 |
2006-10-04 |
叶红平 |
辉伐他汀及其合成方法和以辉伐他汀为原料药的制剂
|
DE602004032465D1
(de)
*
|
2003-12-02 |
2011-06-09 |
Teva Pharma |
Referenzstandard zur charakterisierung von rosuvastatin
|
EP1695706A1
(en)
*
|
2003-12-17 |
2006-08-30 |
Dainippon Sumitomo Pharma Co., Ltd. |
Medicinal compositions and combinations
|
WO2005062824A2
(en)
|
2003-12-23 |
2005-07-14 |
Merck & Co., Inc. |
Anti-hypercholesterolemic compounds
|
US7851624B2
(en)
*
|
2003-12-24 |
2010-12-14 |
Teva Pharamaceutical Industries Ltd. |
Triol form of rosuvastatin and synthesis of rosuvastatin
|
US20070179166A1
(en)
*
|
2003-12-24 |
2007-08-02 |
Valerie Niddam-Hildesheim |
Process for preparation of statins with high syn to anti ratio
|
CA2645396A1
(en)
*
|
2003-12-24 |
2005-07-14 |
Teva Pharmaceutical Industries, Ltd |
Process for preparation of statins with high syn to anti ratio
|
US20070161700A1
(en)
*
|
2004-12-28 |
2007-07-12 |
Kowa Company, Ltd. |
Inhibitor for the formation of y-secretase complex
|
US8163797B2
(en)
*
|
2003-12-31 |
2012-04-24 |
Actavis Elizabeth Llc |
Method of treating with stable pravastatin formulation
|
TWI252253B
(en)
*
|
2004-01-09 |
2006-04-01 |
Chinese Petroleum Corp |
A novel Pseudonocardia sp RMRC PAH4 and a process for bioconverting compactin into pravastatin using the same
|
US20100216863A1
(en)
*
|
2004-01-30 |
2010-08-26 |
Decode Genetics Ehf. |
Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
|
US8158362B2
(en)
*
|
2005-03-30 |
2012-04-17 |
Decode Genetics Ehf. |
Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
|
EP1563837A1
(en)
*
|
2004-02-03 |
2005-08-17 |
Ferrer Internacional, S.A. |
Hypocholesterolemic compositions comprising a statin and an antiflatulent agent
|
US20070078109A1
(en)
*
|
2004-02-13 |
2007-04-05 |
David Platt |
Compositions and methods used to treat acne and candida
|
WO2005079846A1
(ja)
*
|
2004-02-25 |
2005-09-01 |
Kowa Company, Ltd. |
Racタンパク質の核内移行促進剤及びそのスクリーニング方法
|
WO2005079847A1
(ja)
*
|
2004-02-25 |
2005-09-01 |
Kowa Company, Ltd. |
Cdc42タンパク質の核内移行促進剤及びそのスクリーニング方法
|
KR101494067B1
(ko)
|
2004-03-05 |
2015-02-16 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
EP1734819A1
(en)
*
|
2004-03-19 |
2006-12-27 |
Pro-Pharmaceuticals, Inc. |
Compositions and methods for targeting metastatic tumors using multivalent ligand-linked carbohydrate polymers
|
WO2005095374A1
(en)
*
|
2004-03-30 |
2005-10-13 |
Lupin Ltd. |
An improved method for manufacture of 4-hydroxy pyran-2-one derivatives
|
JPWO2005094814A1
(ja)
*
|
2004-03-31 |
2008-02-14 |
興和株式会社 |
外用剤
|
KR100598326B1
(ko)
|
2004-04-10 |
2006-07-10 |
한미약품 주식회사 |
HMG-CoA 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
|
WO2006001877A2
(en)
*
|
2004-04-13 |
2006-01-05 |
Myriad Genetics, Inc. |
Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
|
EP1748761A4
(en)
*
|
2004-05-27 |
2011-10-12 |
Dexcel Pharma Technologies Ltd |
REGULATED AND LOCALIZED ABSORPTION OF STATINS IN THE GASTROINTESTINAL TRACT TO OBTAIN HIGH BLOOD RATE OF STATINS
|
US7803838B2
(en)
*
|
2004-06-04 |
2010-09-28 |
Forest Laboratories Holdings Limited |
Compositions comprising nebivolol
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
US7534763B2
(en)
|
2004-07-02 |
2009-05-19 |
Bristol-Myers Squibb Company |
Sustained release GLP-1 receptor modulators
|
US7145040B2
(en)
*
|
2004-07-02 |
2006-12-05 |
Bristol-Myers Squibb Co. |
Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
|
TW200611704A
(en)
*
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
WO2006017292A1
(en)
*
|
2004-07-12 |
2006-02-16 |
Phenomix Corporation |
Constrained cyano compounds
|
EP1673351A1
(en)
*
|
2004-07-13 |
2006-06-28 |
Teva Pharmaceutical Industries Ltd. |
A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
KR100637762B1
(ko)
*
|
2004-07-30 |
2006-10-23 |
주식회사 지니스 |
저콜레스테롤 란을 생산하기 위한 가금류용 사료첨가제 및 이를 이용한 저콜레스테롤 란의 생산방법
|
US20110217412A1
(en)
*
|
2004-07-30 |
2011-09-08 |
Jinis Biopharmaceuticals Co. |
Cholesterol lowering supplement and low cholesterol egg produced by using the same
|
US20080286251A1
(en)
*
|
2004-08-02 |
2008-11-20 |
Propharmaceuticals, Inc. |
Compositions and Methods for the Enhancement of Chemotherapy with Microbial Cytotoxins
|
NZ552389A
(en)
*
|
2004-08-06 |
2009-05-31 |
Transform Pharmaceuticals Inc |
Statin pharmaceutical compositions and related methods of treatment
|
CA2573316A1
(en)
*
|
2004-08-06 |
2006-02-16 |
Transform Pharmaceuticals, Inc. |
Novel fenofibrate formulations and related methods of treatment
|
US20090042979A1
(en)
*
|
2004-08-06 |
2009-02-12 |
Transform Pharmaceuticals Inc. |
Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006020853A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
US20070244107A1
(en)
*
|
2004-08-25 |
2007-10-18 |
Waters M Gerard |
Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
|
US20060058261A1
(en)
*
|
2004-09-15 |
2006-03-16 |
Andre Aube |
Chitin derivatives for hyperlipidemia
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
EP1809759B1
(en)
|
2004-10-06 |
2013-09-11 |
The Brigham And Women's Hospital, Inc. |
Relevance of achieved levels of markers of systemic inflammation following treatment
|
US7517991B2
(en)
*
|
2004-10-12 |
2009-04-14 |
Bristol-Myers Squibb Company |
N-sulfonylpiperidine cannabinoid receptor 1 antagonists
|
AU2005297984B2
(en)
*
|
2004-10-27 |
2009-11-12 |
Daiichi Sankyo Company, Limited |
Benzene compound having 2 or more substituents
|
CA2588215A1
(en)
*
|
2004-11-22 |
2006-05-26 |
Dexcel Pharma Technologies Ltd. |
Controlled absorption of statins in the intestine
|
TWI307360B
(en)
|
2004-12-03 |
2009-03-11 |
Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag |
Process for constructing strain having compactin hydroxylation ability
|
JP2008523065A
(ja)
|
2004-12-09 |
2008-07-03 |
メルク エンド カムパニー インコーポレーテッド |
エストロゲン受容体モジュレーター
|
TW200619204A
(en)
*
|
2004-12-10 |
2006-06-16 |
Kowa Co |
Method for reduction, stabilization and prevention of rupture of lipid rich plaque
|
BRPI0519919A2
(pt)
*
|
2004-12-15 |
2009-04-07 |
Solvay Pharm Gmbh |
composições farmacêuticas compreendendo inibidores da nep, inibidores do sistema de produção de endotelina endógena e inibidores da hmg coa redutase
|
US7635699B2
(en)
*
|
2004-12-29 |
2009-12-22 |
Bristol-Myers Squibb Company |
Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7589088B2
(en)
*
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US20080194548A1
(en)
*
|
2005-01-06 |
2008-08-14 |
Forrest Michael J |
Drug Combination Therapy and Pharmaceutical Compositions for Treating Inflammatory Disorders
|
US7368458B2
(en)
*
|
2005-01-12 |
2008-05-06 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US7361766B2
(en)
|
2005-01-12 |
2008-04-22 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US7314882B2
(en)
*
|
2005-01-12 |
2008-01-01 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US20060160850A1
(en)
*
|
2005-01-18 |
2006-07-20 |
Chongqing Sun |
Bicyclic heterocycles as cannabinoid receptor modulators
|
AU2006210952B2
(en)
*
|
2005-01-31 |
2011-08-04 |
Mylan Laboratories, Inc. |
Pharmaceutical composition comprising hydroxylated nebivolol
|
JP2007533663A
(ja)
*
|
2005-02-09 |
2007-11-22 |
テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ |
プラバスタチンナトリウムの製造方法
|
DE602006004964D1
(de)
*
|
2005-02-10 |
2009-03-12 |
Bristol Myers Squibb Co |
Dihydrochinazolinone als 5ht-modulatoren
|
US20070037979A1
(en)
*
|
2005-02-22 |
2007-02-15 |
Valerie Niddam-Hildesheim |
Preparation of rosuvastatin
|
US20070167625A1
(en)
*
|
2005-02-22 |
2007-07-19 |
Anna Balanov |
Preparation of rosuvastatin
|
CA2591439C
(en)
*
|
2005-02-22 |
2013-03-26 |
Teva Pharmaceutical Industries Ltd. |
Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
|
US20070293535A1
(en)
*
|
2005-02-24 |
2007-12-20 |
Kowa Company, Ltd. |
Nuclear Transfer Promoter for Ddc42 Protein and Method of Screening the Dame
|
WO2007046842A2
(en)
|
2005-03-02 |
2007-04-26 |
Merck & Co., Inc. |
Composition for inhibition of cathepsin k
|
WO2006103661A2
(en)
*
|
2005-03-28 |
2006-10-05 |
Dexcel Pharma Technologies Ltd. |
Controlled absorption of statins in the intestine
|
EP1879881A2
(en)
|
2005-04-14 |
2008-01-23 |
Bristol-Myers Squibb Company |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
|
WO2006123182A2
(en)
|
2005-05-17 |
2006-11-23 |
Merck Sharp & Dohme Limited |
Cyclohexyl sulphones for treatment of cancer
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
US20060275356A1
(en)
*
|
2005-05-25 |
2006-12-07 |
Burgess James W |
Pharmaceutical compositions for treating or preventing coronary artery disease
|
US7825139B2
(en)
*
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
KR20080026117A
(ko)
*
|
2005-05-26 |
2008-03-24 |
브리스톨-마이어스 스큅 컴퍼니 |
N-말단 개질된 glp-1 수용체 조절제
|
EP2808015A1
(en)
|
2005-05-31 |
2014-12-03 |
Mylan Laboratories, Inc |
Compositions comprising nebivolol
|
US7629342B2
(en)
*
|
2005-06-17 |
2009-12-08 |
Bristol-Myers Squibb Company |
Azabicyclic heterocycles as cannabinoid receptor modulators
|
US7317012B2
(en)
*
|
2005-06-17 |
2008-01-08 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoind-1 receptor modulators
|
US20060287342A1
(en)
*
|
2005-06-17 |
2006-12-21 |
Mikkilineni Amarendra B |
Triazolopyrimidine heterocycles as cannabinoid receptor modulators
|
US7632837B2
(en)
*
|
2005-06-17 |
2009-12-15 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid-1 receptor modulators
|
TW200726765A
(en)
*
|
2005-06-17 |
2007-07-16 |
Bristol Myers Squibb Co |
Triazolopyridine cannabinoid receptor 1 antagonists
|
US7452892B2
(en)
*
|
2005-06-17 |
2008-11-18 |
Bristol-Myers Squibb Company |
Triazolopyrimidine cannabinoid receptor 1 antagonists
|
SG162804A1
(en)
|
2005-06-27 |
2010-07-29 |
Exelixis Inc |
Pyrazole based lxr modulators
|
US20070015832A1
(en)
*
|
2005-07-14 |
2007-01-18 |
Myriad Genetics, Incorporated |
Methods of treating overactive bladder and urinary incontinence
|
AU2006275694A1
(en)
*
|
2005-07-28 |
2007-02-08 |
Bristol-Myers Squibb Company |
Substituted tetrahydro-1H-pyrido(4,3,b)indoles as serotonin receptor agonists and antagonists
|
CN101500555A
(zh)
*
|
2005-08-04 |
2009-08-05 |
变换药品公司 |
包含非诺贝特和他汀的新型制剂及相关治疗方法
|
JP2008515931A
(ja)
*
|
2005-08-16 |
2008-05-15 |
テバ ファーマシューティカル インダストリーズ リミティド |
結晶形ロスバスタチン中間体
|
US7795436B2
(en)
*
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
PE20070335A1
(es)
*
|
2005-08-30 |
2007-04-21 |
Novartis Ag |
Benzimidazoles sustituidos y metodos para su preparacion
|
WO2007030302A2
(en)
*
|
2005-09-01 |
2007-03-15 |
Prescient Medical, Inc. |
Drugs coated on a device to treat vulnerable plaque
|
US20090297496A1
(en)
*
|
2005-09-08 |
2009-12-03 |
Childrens Hospital Medical Center |
Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
|
US20080139457A1
(en)
*
|
2005-09-16 |
2008-06-12 |
Virginia Commonwealth University |
Therapeutic compositions comprising chorionic gonadotropins and HMG CoA reductase inhibitors
|
US8119358B2
(en)
|
2005-10-11 |
2012-02-21 |
Tethys Bioscience, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
DE102005049293A1
(de)
*
|
2005-10-15 |
2007-04-26 |
Bayer Healthcare Ag |
Kombinationspräparate von Salzen oder o-Acetylsalicylsäure
|
WO2007047880A2
(en)
*
|
2005-10-18 |
2007-04-26 |
Aegerion Pharmaceuticals |
Compositions for lowering serum cholesterol and/or triglycerides
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
US8618115B2
(en)
*
|
2005-10-26 |
2013-12-31 |
Bristol-Myers Squibb Company |
Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
|
WO2007053819A2
(en)
|
2005-10-31 |
2007-05-10 |
Bristol-Myers Squibb Company |
Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods
|
WO2007059372A2
(en)
*
|
2005-11-09 |
2007-05-24 |
St. Jude Children's Research Hospital |
Use of chloroquine to treat metabolic syndrome
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
WO2007063866A1
(ja)
*
|
2005-11-29 |
2007-06-07 |
Kyowa Hakko Kogyo Co., Ltd. |
新規蛋白質および該蛋白質をコードするdna
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
US20090018118A1
(en)
*
|
2005-12-29 |
2009-01-15 |
Uros Urleb |
Heterocyclic compounds
|
WO2007082264A2
(en)
*
|
2006-01-11 |
2007-07-19 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
US7553836B2
(en)
*
|
2006-02-06 |
2009-06-30 |
Bristol-Myers Squibb Company |
Melanin concentrating hormone receptor-1 antagonists
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
CA2569776A1
(en)
*
|
2006-02-17 |
2007-08-17 |
Kos Life Sciences, Inc. |
Low flush niacin formulation
|
US20090069275A1
(en)
*
|
2006-02-17 |
2009-03-12 |
Rocca Jose G |
Low flush niacin formulation
|
US20070238770A1
(en)
*
|
2006-04-05 |
2007-10-11 |
Bristol-Myers Squibb Company |
Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
|
ES2654847T3
(es)
|
2006-04-19 |
2018-02-15 |
Novartis Ag |
Compuestos de benzoxazol y benzotiazol sustituidos en 6-O y métodos para inhibir la señalización CSF-1R
|
CA2648936C
(en)
|
2006-04-20 |
2013-07-09 |
Amgen Inc. |
Glp-1 compounds
|
AU2007243282A1
(en)
*
|
2006-04-28 |
2007-11-08 |
Resolvyx Pharmaceuticals, Inc. |
Compositions and methods for the treatment of cardiovascular disease
|
US20070269503A1
(en)
*
|
2006-05-16 |
2007-11-22 |
James Walter Burgess |
Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof
|
EP2021014A1
(en)
*
|
2006-05-26 |
2009-02-11 |
Brystol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
EP2924440A3
(en)
|
2006-06-07 |
2016-03-09 |
Health Diagnostic Laboratory, Inc. |
Markers associated with arteriovascular events and methods of use thereof
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
US20080044326A1
(en)
*
|
2006-07-04 |
2008-02-21 |
Esencia Co., Ltd. |
Sterilizer for baby products
|
MX2008016123A
(es)
|
2006-07-05 |
2009-01-15 |
Nycomed Gmbh |
Combinacion de inhibidores de reductasa hmg-coa con inhibidores de fosfodiesterasa 4 para el tratamiento de enfermedades inflamatorias pulmonares.
|
US7795291B2
(en)
|
2006-07-07 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
|
WO2008006099A2
(en)
*
|
2006-07-07 |
2008-01-10 |
Myriad Genetics, Inc. |
Treatment of psychiatric disorders
|
US7727978B2
(en)
|
2006-08-24 |
2010-06-01 |
Bristol-Myers Squibb Company |
Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
EP2057987B1
(en)
|
2006-08-30 |
2015-03-04 |
Kyushu University, National University Corporation |
Pharmaceutical composition containing statin-encapsulated nanoparticle
|
WO2008039327A2
(en)
|
2006-09-22 |
2008-04-03 |
Merck & Co., Inc. |
Method of treatment using fatty acid synthesis inhibitors
|
US20080118572A1
(en)
*
|
2006-10-10 |
2008-05-22 |
Harold Richard Hellstrom |
Methods and compositions for reducing the risk of adverse cardiovascular events associated with the administration of artificial blood
|
US20100055173A1
(en)
*
|
2006-10-10 |
2010-03-04 |
Adel Penhasi |
Release of statins in the intestine
|
WO2008057862A2
(en)
|
2006-11-01 |
2008-05-15 |
Bristol-Myers Squibb Company |
MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
WO2008079398A1
(en)
*
|
2006-12-21 |
2008-07-03 |
Aegerion Pharmaceuticals, Inc. |
Methods for treating obesity with a combination comprising a mtp inhibitor and a cholesterol absorption inhibitor
|
AU2008204380B2
(en)
|
2007-01-10 |
2013-08-15 |
Msd Italia S.R.L. |
Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
|
CN101679266B
(zh)
|
2007-03-01 |
2015-05-06 |
诺华股份有限公司 |
Pim激酶抑制剂及其应用方法
|
US20090326013A1
(en)
*
|
2007-03-01 |
2009-12-31 |
Curt Hendrix |
Isomers of inositol niacinate and uses thereof
|
CL2008000684A1
(es)
|
2007-03-09 |
2008-08-01 |
Indigene Pharmaceuticals Inc |
Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
|
WO2008112887A1
(en)
*
|
2007-03-13 |
2008-09-18 |
Musc Foundation For Research Development |
Methods of treating juvenile type 1 diabetes mellitus
|
TW200904405A
(en)
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Pharmaceutical formulations containing an SGLT2 inhibitor
|
TWI407955B
(zh)
|
2007-03-29 |
2013-09-11 |
Kowa Co |
高脂血症之預防及/或治療劑
|
WO2008124121A1
(en)
*
|
2007-04-06 |
2008-10-16 |
Scidose, Llc |
Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
|
KR20090127904A
(ko)
*
|
2007-04-09 |
2009-12-14 |
싸이도우스 엘엘씨. |
스타틴과 항비만제의 복합물
|
US20080249156A1
(en)
*
|
2007-04-09 |
2008-10-09 |
Palepu Nageswara R |
Combinations of statins and anti-obesity agent and glitazones
|
WO2008130951A1
(en)
|
2007-04-17 |
2008-10-30 |
Bristol-Myers Squibb Company |
Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
|
BRPI0810409A2
(pt)
|
2007-04-18 |
2015-02-18 |
Thethys Bioscience Inc |
Biomarcadores relacionados ao diabetes e métodos de uso destes
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
ES2425969T3
(es)
|
2007-04-27 |
2013-10-18 |
Kyushu University, National University Corporation |
Agente para el tratamiento de enfermedades pulmonares
|
WO2008144346A2
(en)
*
|
2007-05-18 |
2008-11-27 |
Bristol-Myers Squibb Company |
Crystal structures of sglt2 inhibitors and processes for their preparation
|
BRPI0812159A2
(pt)
|
2007-05-21 |
2017-05-02 |
Novartis Ag |
inibidores de csf-1r, composições e métodos de uso
|
EP2572712A3
(en)
|
2007-06-01 |
2013-11-20 |
The Trustees Of Princeton University |
Treatment of viral infections by modulation of host cell metabolic pathways
|
DE102007028407A1
(de)
|
2007-06-20 |
2008-12-24 |
Bayer Healthcare Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
DE102007028319A1
(de)
|
2007-06-20 |
2008-12-24 |
Bayer Healthcare Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
DE102007028406A1
(de)
|
2007-06-20 |
2008-12-24 |
Bayer Healthcare Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
DE102007028320A1
(de)
|
2007-06-20 |
2008-12-24 |
Bayer Healthcare Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
CA2707360A1
(en)
|
2007-06-20 |
2008-12-24 |
Merck Sharp & Dohme Corp. |
Diphenyl substituted alkanes
|
US8389553B2
(en)
|
2007-06-27 |
2013-03-05 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
US20090011994A1
(en)
*
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
CN101808995A
(zh)
*
|
2007-07-27 |
2010-08-18 |
百时美施贵宝公司 |
新颖的葡糖激酶激活剂及其使用方法
|
US20090076148A1
(en)
*
|
2007-09-14 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched pravastatin
|
CN101801954B
(zh)
*
|
2007-09-20 |
2013-10-09 |
Irm责任有限公司 |
作为gpr119活性调节剂的化合物和组合物
|
WO2009058944A2
(en)
|
2007-11-01 |
2009-05-07 |
Bristol-Myers Squibb Company |
Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and /or nf- kappa b activity and use thereof
|
US20090163452A1
(en)
*
|
2007-12-20 |
2009-06-25 |
Schwartz Janice B |
Compositions and methods for lowering serum cholesterol
|
EP2222636B1
(en)
|
2007-12-21 |
2013-04-10 |
Ligand Pharmaceuticals Inc. |
Selective androgen receptor modulators (sarms) and uses thereof
|
US20090226516A1
(en)
*
|
2008-03-04 |
2009-09-10 |
Pharma Pass Ii Llc |
Sartan compositions
|
US20090226515A1
(en)
*
|
2008-03-04 |
2009-09-10 |
Pharma Pass Ii Llc |
Statin compositions
|
EP2288378A4
(en)
*
|
2008-04-16 |
2011-12-14 |
Univ Utah Res Found |
PHARMACOLOGICAL TARGETING OF VASCULAR MALFORMATION
|
PE20091928A1
(es)
*
|
2008-05-29 |
2009-12-31 |
Bristol Myers Squibb Co |
Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
|
ES2330184B1
(es)
|
2008-06-03 |
2010-07-05 |
Neuron Biopharma, S.A. |
Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores.
|
EP2138178A1
(en)
|
2008-06-28 |
2009-12-30 |
Bayer Schering Pharma Aktiengesellschaft |
Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma
|
EP2161024A1
(de)
|
2008-09-05 |
2010-03-10 |
Universitätsklinikum Hamburg-Eppendorf |
Kombinationspräparat zur Behandlung von Krebs
|
WO2010041619A1
(ja)
|
2008-10-06 |
2010-04-15 |
メルシャン株式会社 |
シュードノカルディア・オートトロフィカ(Pseudonocardia autotrophica)発現ベクター
|
WO2010093601A1
(en)
|
2009-02-10 |
2010-08-19 |
Metabasis Therapeutics, Inc. |
Novel sulfonic acid-containing thyromimetics, and methods for their use
|
MX2011009852A
(es)
|
2009-03-27 |
2011-09-29 |
Bristol Myers Squibb Co |
Metodos para prevenir episodios cardiovasculares adversos mayores con inhibidores de dipeptidil peptidasa iv.
|
EP2413932A4
(en)
|
2009-04-01 |
2012-09-19 |
Merck Sharp & Dohme |
INHIBITORS OF AKT ACTIVITY
|
TW201039815A
(en)
|
2009-04-13 |
2010-11-16 |
Resolvyx Pharmaceuticals Inc |
Compositions and methods for the treatment of inflammation
|
US8470805B2
(en)
*
|
2009-04-30 |
2013-06-25 |
Kaohsiung Medical University |
Processes for preparing piperazinium salts of KMUP and use thereof
|
DK2435410T3
(da)
|
2009-05-28 |
2017-04-10 |
Exelixis Patent Co Llc |
LXR-modulatorer
|
WO2011014520A2
(en)
|
2009-07-29 |
2011-02-03 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
JP2013507366A
(ja)
|
2009-10-09 |
2013-03-04 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
Gpr119活性モジュレーターとしての化合物および組成物
|
BR112012008849A2
(pt)
|
2009-10-14 |
2015-09-22 |
Schering Corp |
composto, composição farmacêutica, e, uso de um composto
|
LT2498758T
(lt)
|
2009-11-13 |
2018-11-26 |
Astrazeneca Ab |
Dvisluoksnės tabletės formuluotės
|
SI2498759T1
(sl)
|
2009-11-13 |
2018-12-31 |
Astrazeneca Ab |
Formulacije tablet s takojšnjim sproščanjem
|
CN102711738A
(zh)
|
2009-11-13 |
2012-10-03 |
百时美施贵宝公司 |
质量得以减小的二甲双胍制剂
|
US8394858B2
(en)
|
2009-12-03 |
2013-03-12 |
Novartis Ag |
Cyclohexane derivatives and uses thereof
|
JP2011121949A
(ja)
|
2009-12-14 |
2011-06-23 |
Kyoto Univ |
筋萎縮性側索硬化症の予防および治療用医薬組成物
|
JP2013518618A
(ja)
|
2010-02-01 |
2013-05-23 |
ザ・ホスピタル・フォー・シック・チルドレン |
再狭窄を治療および予防するための遠隔虚血コンディショニング
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
SG184353A1
(en)
|
2010-03-31 |
2012-11-29 |
Hospital For Sick Children |
Use of remote ischemic conditioning to improve outcome after myocardial infarction
|
SG10201502029RA
(en)
|
2010-04-08 |
2015-05-28 |
Hospital For Sick Children |
Use of remote ischemic conditioning for traumatic injury
|
CN102971313A
(zh)
|
2010-04-14 |
2013-03-13 |
百时美施贵宝公司 |
新颖的葡糖激酶激活剂及其使用方法
|
US8372877B2
(en)
|
2010-04-16 |
2013-02-12 |
Cumberland Pharmaceuticals |
Stabilized statin formulations
|
EP2571860A1
(en)
|
2010-05-21 |
2013-03-27 |
Pfizer Inc |
2-phenyl benzoylamides
|
EP2584903B1
(en)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
PL2590634T3
(pl)
|
2010-07-09 |
2016-10-31 |
|
Skojarzony system natychmiastowego / opóźnionego uwalniania leków o krótkim okresie półtrwania, w tym remogliflozyny
|
US8697739B2
(en)
|
2010-07-29 |
2014-04-15 |
Novartis Ag |
Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
|
JP6043285B2
(ja)
|
2010-08-02 |
2016-12-14 |
サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. |
低分子干渉核酸(siNA)を用いたカテニン(カドヘリン結合型タンパク質)β1(CTNNB1)遺伝子発現のRNA干渉媒介性阻害
|
HUE044815T2
(hu)
|
2010-08-17 |
2019-11-28 |
Sirna Therapeutics Inc |
Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
WO2012036997A1
(en)
|
2010-09-16 |
2012-03-22 |
Schering Corporation |
Fused pyrazole derivatives as novel erk inhibitors
|
WO2012046772A1
(ja)
|
2010-10-06 |
2012-04-12 |
国立大学法人東京大学 |
リンパ浮腫予防治療剤
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
TWI462739B
(zh)
|
2010-11-02 |
2014-12-01 |
Univ Kaohsiung Medical |
Sildenafil-同族物四級銨哌嗪鹽類之製備及醫療用途
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
WO2012085191A1
(en)
|
2010-12-23 |
2012-06-28 |
Dsm Sinochem Pharmaceuticals Netherlands B.V. |
Crystalline form of pravastatine and process for the preparation thereof
|
TWI631963B
(zh)
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
MX351305B
(es)
|
2011-01-20 |
2017-10-09 |
Merck Sharp & Dohme |
Antagonistas del receptor de mineralocorticoides.
|
SI2670486T1
(sl)
|
2011-01-31 |
2016-09-30 |
Cadila Healthcare Limited Zydus Tower Satellite Cross Roads |
Zdravljenje lipodistrofije
|
US8791162B2
(en)
|
2011-02-14 |
2014-07-29 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
WO2012120414A2
(en)
|
2011-03-04 |
2012-09-13 |
Pfizer Inc. |
Edn3-like peptides and uses thereof
|
AR088728A1
(es)
|
2011-03-25 |
2014-07-02 |
Bristol Myers Squibb Co |
Moduladores de lxr como prodroga de imidazol
|
WO2012139495A1
(en)
|
2011-04-13 |
2012-10-18 |
Merck Sharp & Dohme Corp. |
Mineralocorticoid receptor antagonists
|
US20140045847A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
US9505730B2
(en)
|
2011-10-13 |
2016-11-29 |
Merck Sharp & Dohme Corp. |
Mineralocorticoid receptor antagonists
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
KR101466617B1
(ko)
|
2011-11-17 |
2014-11-28 |
한미약품 주식회사 |
오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
|
US20150010630A1
(en)
|
2011-12-29 |
2015-01-08 |
Trustees Of Tufts College |
Functionalization of biomaterials to control regeneration and inflammation responses
|
CN104902892A
(zh)
|
2012-02-02 |
2015-09-09 |
悉尼大学 |
泪液膜稳定性的改进
|
EP3919620A1
(en)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
DK2847228T3
(da)
|
2012-05-10 |
2018-11-19 |
Bayer Pharma AG |
Antistoffer, som kan binde til koagulationsfaktor xi og/eller dens aktiverede form faktor xia, og anvendelser deraf
|
JP6377054B2
(ja)
|
2012-05-11 |
2018-08-22 |
リセット セラピューティークス, インコーポレイテッド |
クリプトクロム調節薬としてのカルバゾール含有スルホンアミド
|
ES2786506T3
(es)
|
2012-08-01 |
2020-10-13 |
Zahra Tavakoli |
Composiciones congeladas fluidas que comprenden un agente terapéutico
|
US8729092B2
(en)
|
2012-09-24 |
2014-05-20 |
Terence J. Scallen |
Rosuvastatin enantiomer compounds
|
WO2014052619A1
(en)
|
2012-09-27 |
2014-04-03 |
Irm Llc |
Piperidine derivatives and compositions as modulators of gpr119 activity
|
US9233979B2
(en)
|
2012-09-28 |
2016-01-12 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
MX365753B
(es)
|
2012-11-20 |
2019-06-12 |
Lexicon Pharmaceuticals Inc |
Inhibidores del contransportador 1 de sodio glucosa.
|
BR112015012295A8
(pt)
|
2012-11-28 |
2023-03-14 |
Merck Sharp & Dohme |
Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
|
BR112015013611A2
(pt)
|
2012-12-20 |
2017-11-14 |
Merck Sharp & Dohme |
composto, e, composição farmacêutica
|
EP2951180B1
(en)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
JP6442475B2
(ja)
|
2013-03-15 |
2018-12-19 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Lxr調節因子
|
CA2907765C
(en)
|
2013-03-21 |
2021-07-06 |
Eupraxia Pharmaceuticals USA LLC |
Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
|
CA2909442A1
(en)
|
2013-04-17 |
2014-10-23 |
Pfizer Inc. |
N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
|
AU2013387996B2
(en)
|
2013-04-22 |
2015-12-10 |
Cadila Healthcare Limited |
A novel composition for nonalcoholic fatty liver disease (NAFLD)
|
WO2014195967A2
(en)
|
2013-05-30 |
2014-12-11 |
Cadila Healthcare Limited |
A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
|
TW201636015A
(zh)
|
2013-07-05 |
2016-10-16 |
卡地拉保健有限公司 |
協同性組成物
|
IN2013MU02470A
(da)
|
2013-07-25 |
2015-06-26 |
Cadila Healthcare Ltd |
|
WO2015027021A1
(en)
|
2013-08-22 |
2015-02-26 |
Bristol-Myers Squibb Company |
Imide and acylurea derivatives as modulators of the glucocorticoid receptor
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
IN2013MU02905A
(da)
|
2013-09-06 |
2015-07-03 |
Cadila Healthcare Ltd |
|
WO2015051479A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
CA2923272A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
JP6536871B2
(ja)
|
2013-12-02 |
2019-07-03 |
国立大学法人京都大学 |
Fgfr3病の予防および治療剤ならびにそのスクリーニング方法
|
EP3613418A1
(en)
|
2014-01-17 |
2020-02-26 |
Ligand Pharmaceuticals, Inc. |
Methods and compositions for modulating hormone levels
|
WO2015120580A1
(en)
|
2014-02-11 |
2015-08-20 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
TWI690521B
(zh)
|
2014-04-07 |
2020-04-11 |
美商同步製藥公司 |
作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
|
CN106572997A
(zh)
|
2014-05-30 |
2017-04-19 |
辉瑞公司 |
作为选择性雄激素受体调节剂的腈衍生物
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
WO2016044021A1
(en)
|
2014-09-15 |
2016-03-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Targeting aneurysm disease by modulating phagocytosis pathways
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
US11253588B2
(en)
|
2015-02-27 |
2022-02-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Combination therapy for treatment of coronary artery disease
|
KR20170138570A
(ko)
|
2015-04-30 |
2017-12-15 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
대사 장애를 치료하기 위한 항-aP2 항체 및 항원 결합 물질
|
US10385017B2
(en)
|
2015-10-14 |
2019-08-20 |
Cadila Healthcare Limited |
Pyrrole compound, compositions and process for preparation thereof
|
CA3003159A1
(en)
|
2015-10-27 |
2017-05-04 |
Eupraxia Pharmaceuticals Inc. |
Sustained release formulations of local anesthetics
|
BR112019011740A2
(pt)
|
2016-12-09 |
2019-10-29 |
Cadila Healthcare Ltd |
composição farmacêutica e método para o tratamento de colangite biliar primária
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2019216313A1
(ja)
|
2018-05-08 |
2019-11-14 |
国立大学法人岡山大学 |
心血管疾患に有用な医薬
|
PE20210644A1
(es)
|
2018-07-19 |
2021-03-23 |
Astrazeneca Ab |
METODOS DE TRATAMIENTO DE HFpEF EMPLEANDO DAPAGLIFLOZINA Y COMPOSICIONES QUE COMPRENDEN LA MISMA
|
EP3824912A4
(en)
|
2018-07-19 |
2022-04-20 |
Kyoto University |
PLATEFORM CARTILAGE DERIVED FROM PLURIPOTENTS STEM CELLS AND METHODS FOR PRODUCTION OF PLATEFORM CARTILAGE
|
EP3833667B1
(en)
|
2018-08-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
US10968192B2
(en)
|
2018-09-26 |
2021-04-06 |
Lexicon Pharmaceuticals, Inc. |
Crystalline solid forms of N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide and methods of their synthesis
|
EP3900787A4
(en)
|
2018-12-21 |
2022-02-23 |
Kyoto University |
CARTILAGE-LIKE TISSUE WITH LOCALIZED LUBRICINE, METHOD FOR THE PRODUCTION THEREOF, AND COMPOSITION COMPRISING IT FOR THE TREATMENT OF ARTICULAR CARTILAGE LESIONS
|
CN113574055A
(zh)
|
2019-01-18 |
2021-10-29 |
阿斯利康(瑞典)有限公司 |
Pcsk9抑制剂及其使用方法
|
SG11202109928WA
(en)
|
2019-03-13 |
2021-10-28 |
National Univ Corporation Hamamatsu Univ School Of Medicine |
Pharmaceutical composition for treating aortic aneurysm
|
MX2021014552A
(es)
|
2019-05-27 |
2022-02-11 |
Immatics Us Inc |
Vectores viricos y uso de los mismos en terapias celulares adoptivas.
|
US20230108452A1
(en)
|
2019-12-17 |
2023-04-06 |
Merck Sharp & Dohme Llc |
Prmt5 inhibitors
|
WO2021167088A1
(ja)
|
2020-02-21 |
2021-08-26 |
良和 中岡 |
肺高血圧症改善用組成物、肺高血圧症の予後予測方法、肺高血圧症の重症度判定補助方法および肺高血圧症の診断補助方法
|
DE102020111571A1
(de)
|
2020-03-11 |
2021-09-16 |
Immatics US, Inc. |
Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
|
US20220023252A1
(en)
|
2020-07-27 |
2022-01-27 |
Astrazeneca Ab |
Methods of treating chronic kidney disease with dapagliflozin
|
TW202227616A
(zh)
|
2020-08-21 |
2022-07-16 |
美商英麥提克斯股份有限公司 |
分離cd8+選擇t細胞的方法
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|
WO2023144722A1
(en)
|
2022-01-26 |
2023-08-03 |
Astrazeneca Ab |
Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
|